Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease

• by Fleur Kleiburg, Linda Heijmen, Annemieke Witteveen, Kiki van Duuren, Paul Zuidgeest, Frits Smit, Lioe-Fee de Geus-Oei, Tom van der Hulle

• September 16, 2026

The evolution of RTOG and NRG Oncology CNS tumors clinical trials

• by Kavita Sehrawat, Mei-Yin C. Polley, Michael A. Vogelbaum, Mark Gilbert, Arnab Chakravarti, Daniel P. Cahill, Andrew B. Lassman, David R. Raleigh, Erik P. Sulman, Mitch Machtay, Quynh Thu Le, Walter Curran, Vinai Gondi, Minesh P. Mehta

• September 15, 2026

Medicaid Expansion and Mortality Among Patients With Colorectal Cancer

• by Oluwasegun Akinyemi, Oladayo Oyebanji, Babawale Oluborode, Bolarinwa Akinwumi, Fadeke Ogunyankin, Kakra Hughes, Terrence Fullum, Quyen Chu, Surya Nalamati, Marwan Abouljoud, Christine Nembhard, Craig Reickert

• September 18, 2026

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

• September 16, 2026

• 2 min